All about the Deepbridge Life Sciences SEIS Fund
For over 40 years, the UK life sciences industry has been one of the most successful on a global basis. In 2012, the UK Government published the Strategy for UK Life Sciences, acknowledging the changing nature of the health life sciences sector, with a growing number of SMEs playing a leading role in driving growth.
The Deepbridge Life Sciences SEIS intends to participate in this changing business environment, securing compelling investment opportunities derived from a long-lasting legacy of scientific research and innovation in the United Kingdom.
The fund aims to invest in a diversified portfolio of early-stage life science companies that qualify fo the considerable income tax, capital gains tax, and inheritance tax benefits of the Seed Enterprise Investment Scheme.
The fund will invest in up to 10 seed-stage life sciences companies operating in the following areas:
• Biopharmaceuticals • Biotechnology • Medical Technology
These types of company may focus on any of the following:
• Anti-viral drug discovery and development • Antibiotic drug discovery and development • Neurodegenerative disease therapeutics • Cancer diagnostics and therapeutics • Autoimmune and other metabolic disorders therapies.
In addition to investment by Deepbridge, Deepbridge aim to help companies with non-dilutive matched funding from regional development funds, as well as research grant funding, both provided on an unsecured basis.
Deepbridge will add further value to Investee Companies by taking a seat on the Board of Directors and using an extensive industry network to access advice and commercial support to the business.
Summary
| Fund Manager: | Deepbridge Capital |
| Tax Efficiency: | SEIS |
| Sector Focus: | Technology |
| Stage Focus: | Seed |
| Target Portfolio Size: | 6-10 companies |
| Minimum Subscription: | £10,000 |
| Closing Date: | Currently closed |
| Website: | Learn more about Deepbridge Life Sciences SEIS Fund |
Pros & Cons
Pros: Investors who come through advisors pay no fees so the full of their investment into the fund is deployed and thus is eligible for SEIS relief. Deepbridge Capital was founded in 2010 and is an established firm that runs multiple SEIS, EIS and other tax-efficient funds.
Cons: While no fees for investors is a good thing the fees to the companies mean they have less capital to operate the business and are required to pay the fund manager until there is an exit for the business.
Fees
| Full initial fee: | 2.5% direct, 0% advised |
| Annual management fee: | nil |
| Administration fee | nil |
| Performance fee: | 20% of cash returned in excess of 150% of the funds invested |
Investee company fees
| Dealing fee: | 0.65% on purchase of shares |
| Annual maintenance fee: | 2% of the funds invested in the company |
| Annual custody: | 0.5% |
How does SyndicateRoom's Access EIS Fund compare?
By comparison, SyndicateRoom's Access EIS fund builds investors a large portfolio of 50+ companies across all sectors, co-investing with experienced angel investors who have an average IRR of 42%. Our model is based on our proprietary analysis of the UK startup market, which showed that on average, the market grows by 28% each year. With large portfolios, and a large network of angels providing access to the best deals, earlier, we aim to replicate that annual growth for our investors while mitigating risk. This data-driven approach aims to work around the limitations of a single fund manager attempting to pick winners.
Our minimum investment is £5,000.
| Fund Manager: | SyndicateRoom |
| Tax Efficiency: | EIS |
| Sector Focus: | Sector Agnostic |
| Stage Focus: | Early-stage |
| Target Portfolio Size: | 50+ companies |
| Minimum Subscription: | £5,000 |
| Closing Date: | Evergreen |
| Website: | Learn more about the Access EIS Fund |
Are you the fund manager? Email tom@syndicateroom.com with any comments or amends.